N-(3-氨基丙基)半胱氨酸 | 51785-96-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(3-氨基丙基)半胱氨酸
• 中文别名: 2-丙烯酸,亚硫酸氢调聚物和钠,盐铵
• 英文名称: S-3-Aminopropyl-L-cystein
• 英文别名: L-(S-(3-aminopropyl)cysteine)；Aminopropylcysteine；(2R)-2-amino-3-(3-aminopropylsulfanyl)propanoic acid
• CAS: 51785-96-7
• 化学式: C₆H₁₄N₂O₂S
• 分子量: 178.255
• InChiKey: KLGFHUHSBPGOAU-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  N-(3-氨基丙基)半胱氨酸 在 snake venom type VI L-amino acid oxidase 作用下， 以 various solvent(s) 为溶剂， 生成 2,5,6,7-Tetrahydro-[1,4]thiazepine-3-carboxylic acid
  参考文献：
  名称：

  Enzymatic synthesis of cyclic amino acids by N-methyl-l-amino acid dehydrogenase from Pseudomonas putida

  摘要：

  A new enzymatic system for the synthesis of enantiomerically pure cyclic amino acids (CAA) from the corresponding diamino acids or racemic CAA is described. alpha,omega-Diamino acids were oxidized to alpha-keto acids with amino acid oxidases (AAO). The alpha-keto acids were spontaneously transformed into cyclic imino acids in the reaction medium. The resulting imines were reduced to the L-form CAA with N-methyl-L-amino acid dehydrogenase (NMAADH) from Pseudomonas putida ATCC12633 using NADPH as a cofactor. L-Form CAA were also obtained from racemic CAA using D-amino-acid oxidase and NMAADH. Using this method, a new compound [1,4]thiazepane-3-carboxylic acid (Fig. 1) was synthesized from aminopropylcystein. (c) 2006 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetasy.2006.07.005

文献信息

• [EN] ANTI-CANCER COMPOUNDS AND METHODS RELATED THERETO<br/>[FR] COMPOSES ANTICANCEREUX ET PROCEDES S'Y RAPPORTANT
  申请人：STEWART JOHN M

  公开号：WO2000011022A1

  公开（公告）日：2000-03-02

  The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula (I): [ACA]n-X wherein, X is a linker group having 2-5 functional groups or is absent, n = 1, and ACA is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V), and Formula (VI), as described herein. Other compounds described herein are defined by the Formula (VII), as described herein.

  本发明提供了一种有用的化合物，可用于抑制肿瘤生长和诱导细胞凋亡。一般来说，抗癌药物（ACA）由公式（I）描述：[ACA]n-X其中，X是具有2-5个功能基团的连接基团或不存在，n = 1，而ACA选自本文所述的公式（II），公式（III），公式（IV），公式（V）和公式（VI）的群组。本文还描述了其他化合物，其由公式（VII）所定义，如本文所述。
• COMPOUNDS AS APTAMER-DIMERS AND THEIR USES IN DIAGNOSIS AND THERAPY
  申请人：Friebe Matthias

  公开号：US20080207523A1

  公开（公告）日：2008-08-28

  The object of the present invention is solved by compositions of peptide linkers and their use for synthesis and annealing of aptamer oligonucleotides in form of dimers. The present invention in particularly provides said compositions for the use as a diagnostic and/or therapeutic agent. In another preferred embodiment the present invention relates to a kit for preparing a radiopharmaceutical preparation, said kit comprising a vial comprising a quantity of the compound according to the invention. A further preferred embodiment of the present invention relates to methods of producing said compounds, comprising synthesis of said compound in an automated peptide synthesizer. In another preferred embodiment the present invention concerns the use of said compounds according to the present invention for the manufacture of a medicament, preferably for diagnosis or therapy of proliferative diseases. In a further preferred embodiment the present invention concerns methods for treating or diagnosing patients administering or utilizing the compounds according to the present invention.

  本发明的目的是通过肽链连接物的组合及其用于二聚体形式的适配体寡核苷酸的合成和退火来解决。本发明特别提供了上述组合物，用作诊断和/或治疗剂。在另一种优选实施方式中，本发明涉及用于制备放射性药物制剂的试剂盒，该试剂盒包括含有本发明的化合物数量的小瓶。本发明的另一种优选实施方式涉及生产所述化合物的方法，包括在自动化肽合成仪中合成所述化合物。在本发明的另一种优选实施方式中，本发明涉及使用本发明的化合物制造药物，优选用于增殖性疾病的诊断或治疗。在本发明的另一种优选实施方式中，本发明涉及使用本发明的化合物治疗或诊断患者的方法。
• Radioactively-labeled somatostatin derived peptides for imaging and therapeutics uses
  申请人：Diatide, Inc.

  公开号：EP1092726A2

  公开（公告）日：2001-04-18

  This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (186Re) and rhenium-188 (188Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.

  本发明涉及治疗试剂和肽，包括放射性治疗试剂和肽、放射性诊断试剂和肽，以及生产标记放射性诊断剂的方法。具体地说，本发明涉及体生长抑素的环肽衍生物和类似物，以及用放射性同位素进行放射性标记的这种肽的实施方案，以及制造、放射性标记和使用这种肽用于放射诊断和放射治疗目的的方法和试剂盒。本发明具体涉及用锝-99m 放射性标记的环肽衍生物和体生长抑素类似物及其作为闪烁成像剂的用途。本发明还特别涉及用铼-186（186Re）和铼-188（188Re）等细胞毒性放射性同位素放射性标记的环肽衍生物和类似物，用作放射治疗剂。此外，还提供了用于制造、放射性标记和在哺乳动物体内诊断和治疗使用这种肽的方法和试剂盒。
• Radioactively-labeled somatostatin derived peptides for imaging and therapeutic uses
  申请人：Diatide, Inc.

  公开号：EP1094074A2

  公开（公告）日：2001-04-25

  This invention relates to therapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to peptide derivatives and analogs of somatostatin, and embodiments of such peptides labeled with technetium-99m (Tc-99m), as well as methods and kits for making, radiolabeling and using such peptides to image sites in a mammalian body. The invention also relatees to peptide derivatives and analogues of somatostantin labeled with rhenium-186 (186Re) and rhenium-188 (188Re), and methods and kits for making, radiolabeling and using such peptides therapeutically in a mammalian body.

  本发明涉及治疗试剂和肽、放射性诊断试剂和肽，以及生产标记放射性诊断剂的方法。具体而言，本发明涉及体生长抑素的肽衍生物和类似物，以及用锝-99m（Tc-99m）标记的此类肽的实施方案，以及制造、放射性标记和使用此类肽对哺乳动物体内的部位进行成像的方法和试剂盒。本发明还涉及用铼-186（186Re）和铼-188（188Re）标记的肽衍生物和类似物，以及在哺乳动物体内制造、放射性标记和使用这种肽进行治疗的方法和试剂盒。
• Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses
  申请人：Diatide, Inc.

  公开号：EP1099707A2

  公开（公告）日：2001-05-16

  This invention relates to therapeutic reagents and peptides, including radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic agents. Specifically, the invention relates to cyclic peptide derivatives and analogs of somatostatin, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to cyclic peptide derivatives and analogues of somatostatin radiolabeled with cytotoxic radioisotopes such as rhenium-186 (186Re) and rhenium-188 (188Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.

  本发明涉及治疗试剂和肽，包括放射性治疗试剂和肽、放射性诊断试剂和肽，以及生产标记放射性诊断剂的方法。具体地说，本发明涉及体生长抑素的环肽衍生物和类似物，以及用放射性同位素进行放射性标记的这种肽的实施方案，以及制造、放射性标记和使用这种肽用于放射诊断和放射治疗目的的方法和试剂盒。本发明具体涉及用锝-99m 放射性标记的环肽衍生物和体生长抑素类似物及其作为闪烁成像剂的用途。本发明还特别涉及用铼-186（186Re）和铼-188（188Re）等细胞毒性放射性同位素放射性标记的环肽衍生物和类似物，用作放射治疗剂。此外，还提供了用于制造、放射性标记和在哺乳动物体内诊断和治疗使用这种肽的方法和试剂盒。